Colecalciferol/risedronic acid - DaewoongAlternative Names: IMD 7; Incrementally modified drug 7; Risen Plus Tablet
Latest Information Update: 20 Aug 2013
At a glance
- Originator Daewoong Pharmaceutical
- Class Adjuvants; Bisphosphonates; Calcium regulators; Cholestenes; Osteoporosis therapies; Small molecules; Sterols; Vitamin D analogues
- Mechanism of Action Bone resorption factor inhibitors; HMG-CoA reductase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed Osteoporosis
Most Recent Events
- 18 Jun 2013 Launched for Osteoporosis in South Korea (PO)